AxoGen, Inc. (AXGN) vs NovoCure Limited (NVCR)
AxoGen, Inc. and NovoCure Limited are both Medical Devices companies. AxoGen, Inc. is the larger, with a market value of $2.5B against $1.9B — 1.3× the size. AxoGen, Inc. grew revenue faster over the last twelve months: 23.6% against 11.0%. AxoGen, Inc. has the higher net margin (−13.4% vs −21.3%) and the higher return on invested capital (−4.99% vs −115.6%). Across the 18 metrics below, AxoGen, Inc. leads on 12 and NovoCure Limited on 6.
Valuation
Profitability
| Metric | AXGN | NVCR | Medical Devices median |
|---|---|---|---|
| Gross margin | 74.56% | 76.13% | 56.01% |
| Operating margin | (5.12%) | (22.08%) | (15.03%) |
| Net margin | (13.36%) | (21.25%) | (20.40%) |
| Free cash flow margin | 2.59% | (3.64%) | (7.24%) |
| Return on equity | (18.21%) | (43.22%) | (15.32%) |
| Return on assets | (13.15%) | (14.56%) | (19.72%) |
| Return on invested capital | (4.99%) | (115.56%) | (10.33%) |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack